UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/562,197	05/09/2006	Nava Zisapel	2007-123	4120
ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W. SUITE 800			EXAMINER	
			DAVIS, BRIAN J	
WASHINGTON, DC 20005		ART UNIT	PAPER NUMBER	
			1621	
			NOTIFICATION DATE	DELIVERY MODE
			01/26/2011	ELECTRONIC

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTO-PAT-Email@rfem.com

	Application No.	Applicant(s)		
	10/562,197	ZISAPEL ET AL.		
Office Action Summary	Examiner	Art Unit		
	Brian J. Davis	1621		
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period v Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
<ul> <li>1) Responsive to communication(s) filed on 18 Ja</li> <li>2a) This action is FINAL. 2b) This</li> <li>3) Since this application is in condition for alloware closed in accordance with the practice under E</li> </ul>	action is non-final. nce except for formal matters, pro			
Disposition of Claims				
<ul> <li>4)  Claim(s) 1-37 is/are pending in the application 4a) Of the above claim(s) 2,3,5-7,10-14,16-18,.</li> <li>5)  Claim(s) 8 is/are allowed.</li> <li>6)  Claim(s) 1,4,9,15,19,26,28-30,32,33,35 and 33, 7)  Claim(s) is/are objected to.</li> <li>8)  Claim(s) are subject to restriction and/o</li> </ul>	<i>20-25,27,31,34 and 36</i> is/are with Zis/are rejected.	drawn from consideration.		
Application Papers				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)			
Notice of Draftsperson's Patent Drawing Review (P10-948)     Information Disclosure Statement(s) (PTO/SB/08)     Paper No(s)/Mail Date	5) Notice of Informal P			

### **DETAILED ACTION**

#### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/18/11 has been entered.

# 102 Rejections Withdrawn

The rejection of claims 1, 4, 15, 16, 25, 26, 28, 28 and 32, in so far as they read on the species defined in the previous Office Action, under 35 USC 102(b), has been overcome by applicant's amendment. The amendment narrows the claim set such that is no longer reads on the cited art.

# Allowable Subject Matter

Claim 8, drawn exclusively to the elected species, remains free of the prior art.

# Claim Rejections - 35 USC § 102

Applicant having overcome the outstanding art rejection, the search was expanded as called for under Markush examination rules, a compound-by-compound

Art Unit: 1621

search, to include a single additional compound. That compound is defined when, using formula (I) of claim 1:  $R=R_1=R_2=H$ ;  $A=C_2$  alkylene;  $X=C_2$  (branched) alkylene; and Y=arylalkyl.

All claimed subject matter which does not read on the above species is considered non-elected subject matter for purposes of this Office Action and as such is withdrawn from consideration.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 4, 9, 15, 19, 26, 28-30, 32, 33, 35 and 37, in so far as they read on the species defined above, are rejected under 35 U.S.C. 102(b) as being clearly anticipated by *Bollettino Chimico Farmaceutico* (1964), 103(3), p. 165-170 (CAPLUS abstract). The reference teaches applicant's compound: RN=99690-18-3. The compound is among those evaluated for pharmaceutical use.

(The subject matter of the remaining claims is withdrawn as being drawn to nonelected subject matter.)

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian J. Davis whose telephone number is 571-272-0638. The examiner can normally be reached on M-F 8:30-5:00.

Application/Control Number: 10/562,197 Page 4

Art Unit: 1621

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Daniel M. Sullivan can be reached at 571-272-0779. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Brian J. Davis/ Primary Examiner, Art Unit 1621 1/20/11